0-9 | A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z


Part of Minutes of the University of Kentucky Board of Trustees

item | thumbnails | details | text | pdf
Download this image
Summary: Dr. Webb and Mr. Kroemer have identified a class of proteins whose increased presence increases longevity of and protein production in cells. Specifically, they provide methods of increasing the levels of the identified proteins in cells to take advantage of the increased longevity and protein production. 5. U.S. Patent Application Serial Number: (to be assigned) Filed: January 3, 2005 Title: "Bis-Pyridino Containing Compounds for Use in the Treatment of CNS Pathologies" Inventors: Dr. Peter A. Crooks, Mr. Joshua T. Ayers, Dr. Vladimir Grinevich, and Dr. Sageetha P. Sumithran. Technical Description: The present invention provides N-n-Alkylation of nicotine which converts nicotine from an agonist into an antagonist specifically for neuronal nicotinic acetylcholine receptor subtypes mediating nicotine-evoked dopamine release. Conformationally restricted analogs exhibit both high affinity and selectivity at this site, and are able to access the brain due to their ability to act as substrates for the blood-brain barrier choline transporter. Summary: Drs. Crooks, Grinevich, and Sumithran and Mr. Ayers have chemically altered nicotine. This altered form of nicotine can pass into the brain, blocking the effect of nicotine and natural nicotine-like compounds on a subset of neurons. These compounds can be used to study diseases such as myasthenia gravis, Parkinson's disease, Alzheimer's disease, schizophrenia, eating disorders, and drug addiction. 6. U.S. Patent Application Serial Number: (to be assigned) Filed: January 12, 2005 Titled: "Method for Protecting Against Neurological Damage Following Acute Neurological Insult" Inventor: Dr. William F. Maragos. Technical Description: The present invention provides a method for protecting against neuronal damage following an acute neurological insult and comprises identifying a patient who has been subjected to the acute neurological insult; providing a mitochondrial uncoupler; and administering a neuroprotective dose of the mitochondrial uncoupler to the patient during a therapeutic window, which extends from immediately following the acute neurological insult, wherein a neuroprotective effect is produced. Summary: Dr. Maragos has invented a method for treating some forms of brain injury, such as stroke. The method represents a new use for a drug that is not currently used therapeutically. That drug belongs to a class of drugs known as "mitochondrial uncouplers" that promote cell survival.